GEMMILY
Post-LOEnorethindrone acetate and ethinyl estradiol, and ferrous fumarate
ANDAORALCAPSULE
Approved
Nov 2020
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
3/8 — Basic
GEMMILY (norethindrone acetate and ethinyl estradiol, and ferrous fumarate) by Ichnos Glenmark Innovation is ovulation. First approved in 2020.
Drug data last refreshed 18h ago
$0.0BPart D
Mechanism of Action
ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on GEMMILY at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.